Soren Lehmann

Publications
CV
Public outreach and news

Articles

Article: HAEMATOLOGICA. 2021;106(10):2566-2577

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells.

Hultmark S; Baudet A; Schmiderer L; Prabhala P; Palma-Tortosa S; Sandén C; Fioretos T; Sasidharan R; Larsson C; Lehmann S; Juliusson G; Ek F; Magnusson M
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.

Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
Article: GENES CHROMOSOMES & CANCER. 2021;60(6):426-433

Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.

Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(5):580-588

The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia.

Mou T; Pawitan Y; Stahl M; Vesterlund M; Deng W; Jafari R; Bohlin A; Österroos A; Siavelis L; Bäckvall H; Erkers T; Kiviluoto S; Seashore-Ludlow B; Östling P; Orre LM; Kallioniemi O; Lehmann S; Lehtiö J; Vu TN
Article: BLOOD ADVANCES. 2021;5(4):1003-1016

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Mareschal S; Palau A; Lindberg J; Ruminy P; Nilsson C; Bengtzén S; Engvall M; Eriksson A; Neddermeyer A; Marchand V; Jansson M; Björklund M; Jardin F; Rantalainen M; Lennartsson A; Cavelier L; Grönberg H; Lehmann S
Article: NATURE COMMUNICATIONS. 2021;12(1):1054

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML.

Mer AS; Heath EM; Madani Tonekaboni SA; Dogan-Artun N; Nair SK; Murison A; Garcia-Prat L; Shlush L; Hurren R; Voisin V; Bader GD; Nislow C; Rantalainen M; Lehmann S; Gower M; Guidos CJ; Lupien M; Dick JE; Minden MD; Schimmer AD; Haibe-Kains B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Article: BLOOD. 2020;136(3):339-352

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.

Mujahed H; Miliara S; Neddermeyer A; Bengtzén S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Article: CLINICAL CANCER RESEARCH. 2020;26(14):3597-3607

RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia.

Anande G; Deshpande NP; Mareschal S; Batcha AMN; Hampton HR; Herold T; Lehmann S; Wilkins MR; Wong JWH; Unnikrishnan A; Pimanda JE
Article: GENOME BIOLOGY. 2020;21(1):153

Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs.

Do C; Dumont ELP; Salas M; Castano A; Mujahed H; Maldonado L; Singh A; DaSilva-Arnold SC; Bhagat G; Lehman S; Christiano AM; Madhavan S; Nagy PL; Green PHR; Feinman R; Trimble C; Illsley NP; Marder K; Honig L; Monk C; Goy A; Chow K; Goldlust S; Kaptain G; Siegel D; Tycko B
Article: BLOOD CANCER JOURNAL. 2020;10(6):67

Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia.

Österroos A; Björklund M; Eriksson A; Lindberg J; Nilsson C; Mareschal S; Rantalainen M; Grönberg H; Lehmann S
Article: BLOOD ADVANCES. 2020;4(6):1094-1101

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting.

Juliusson G; Jädersten M; Deneberg S; Lehmann S; Möllgård L; Wennström L; Antunovic P; Cammenga J; Lorenz F; Ölander E; Lazarevic VL; Höglund M
Article: EMBO MOLECULAR MEDICINE. 2020;12(3):e10419

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter J-I; Schaller T; Helleday T; Herold N
Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(29):2632-2642

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas P-Y; Dombret H; Preudhomme C; Micol J-B; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch J-H; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1770-1778

Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting.

Nilsson C; Hulegårdh E; Garelius H; Möllgård L; Brune M; Wahlin A; Lenhoff S; Frödin U; Remberger M; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(10):1094-1101

Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.

Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Grönberg H; Rantalainen M
Article: SCIENTIFIC REPORTS. 2018;8(1):11293

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.

Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerland MC; Berdel WE; Wörmann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix A-L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Article: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2018;11(1):52

Expression levels of long non-coding RNAs are prognostic for AML outcome.

Mer AS; Lindberg J; Nilsson C; Klevebring D; Wang M; Grönberg H; Lehmann S; Rantalainen M
Article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;117:247-257

Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis.

Khalkar P; Ali HA; Codó P; Argelich ND; Martikainen A; Arzenani MK; Lehmann S; Walfridsson J; Ungerstedt J; Fernandes AP
Article: LEUKEMIA. 2017;31(10):2029-2036

Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.

Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Grönberg H
Article: CANCER IMMUNOLOGY RESEARCH. 2017;5(8):654-665

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.

Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg K-J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(5):493-500

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.

Lazarevic VL; Rosso A; Juliusson G; Antunovic P; Derolf ÅR; Deneberg S; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Lehmann S; Johansson B
Article: LEUKEMIA. 2017;31(5):1108-1116

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M; Olsson-Strömberg U; Schlums H; Guilhot J; Brück O; Lähteenmäki H; Kasanen T; Koskenvesa P; Söderlund S; Höglund M; Markevärn B; Själander A; Lotfi K; Dreimane A; Lübking A; Holm E; Björeman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon F-X; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Article: ONCOTARGET. 2017;8(17):28812-28825

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
Article: BLOOD. 2017;129(7):e13-e25

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.

Qu Y; Siggens L; Cordeddu L; Gaidzik VI; Karlsson K; Bullinger L; Döhner K; Ekwall K; Lehmann S; Lennartsson A
Article: NATURE MEDICINE. 2017;23(2):256-263

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CBJ; Heshmati Y; Hagenkort A; Kutzner J; Page BDG; Calderón-Montaño JM; Loseva O; Jemth A-S; Bulli L; Axelsson H; Tesi B; Valerie NCK; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter J-I; Helleday T; Schaller T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(1):117-126

Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells.

Ali D; Mohammad DK; Mujahed H; Jonson-Videsäter K; Nore B; Paul C; Lehmann S
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(9):800-805

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.

Lazarevic V; Rosso A; Juliusson G; Antunovic P; Rangert-Derolf Å; Lehmann S; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Johansson B
Article: EXPERIMENTAL HEMATOLOGY. 2015;43(8):609-624

Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis.

Eriksson A; Lennartsson A; Lehmann S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(5):419-423

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.

Lazarevic V; Hörstedt A-S; Johansson B; Antunovic P; Billström R; Derolf Å; Lehmann S; Möllgård L; Peterson S; Stockelberg D; Uggla B; Vennström L; Wahlin A; Höglund M; Juliusson G
Article: LEUKEMIA. 2015;29(5):1084-1091

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Lengfelder E; Lo-Coco F; Ades L; Montesinos P; Grimwade D; Kishore B; Ramadan SM; Pagoni M; Breccia M; Huerta AJG; Nloga AM; González-Sanmiguel JD; Schmidt A; Lambert J-F; Lehmann S; Di Bona E; Cassinat B; Hofmann W-K; Görlich D; Sauerland M-C; Fenaux P; Sanz M; European LeukemiaNet
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(3):208-214

Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.

Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(26):2477-2487

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Genovese G; Kähler AK; Handsaker RE; Lindberg J; Rose SA; Bakhoum SF; Chambert K; Mick E; Neale BM; Fromer M; Purcell SM; Svantesson O; Landén M; Höglund M; Lehmann S; Gabriel SB; Moran JL; Lander ES; Sullivan PF; Sklar P; Grönberg H; Hultman CM; McCarroll SA
Article: EPIGENETICS. 2014;9(8):1108-1119

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.

Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzén S; Höglund M; Bullinger L; Döhner K; Lehmann S
Article: BMC GENOMICS. 2014;15(1):487

Relationship between genome and epigenome--challenges and requirements for future research.

Almouzni G; Altucci L; Amati B; Ashley N; Baulcombe D; Beaujean N; Bock C; Bongcam-Rudloff E; Bousquet J; Braun S; Bressac-de Paillerets B; Bussemakers M; Clarke L; Conesa A; Estivill X; Fazeli A; Grgurević N; Gut I; Heijmans BT; Hermouet S; Houwing-Duistermaat J; Iacobucci I; Ilaš J; Kandimalla R; Krauss-Etschmann S; Lasko P; Lehmann S; Lindroth A; Majdič G; Marcotte E; Martinelli G; Martinet N; Meyer E; Miceli C; Mills K; Moreno-Villanueva M; Morvan G; Nickel D; Niesler B; Nowacki M; Nowak J; Ossowski S; Pelizzola M; Pochet R; Potočnik U; Radwanska M; Raes J; Rattray M; Robinson MD; Roelen B; Sauer S; Schinzer D; Slagboom E; Spector T; Stunnenberg HG; Tiligada E; Torres-Padilla M-E; Tsonaka R; Van Soom A; Vidaković M; Widschwendter M
Article: EPIGENETICS. 2014;9(6):910-917

microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.

Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
Article: BLOOD. 2014;123(17):e79-e89

Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation.

Rönnerblad M; Andersson R; Olofsson T; Douagi I; Karimi M; Lehmann S; Hoof I; de Hoon M; Itoh M; Nagao-Sato S; Kawaji H; Lassmann T; Carninci P; Hayashizaki Y; Forrest ARR; Sandelin A; Ekwall K; Arner E; Lennartsson A; FANTOM consortium
Article: BLOOD CANCER JOURNAL. 2014;4(2):e188

Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.

Lazarevic V; Hörstedt A-S; Johansson B; Antunovic P; Billström R; Derolf A; Hulegårdh E; Lehmann S; Möllgård L; Nilsson C; Peterson S; Stockelberg D; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G
Article: BLOOD. 2013;122(7):1284-1292

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Höglund M; Sandin F; Hellström K; Björeman M; Björkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevärn B; Myhr-Eriksson K; Ohm L; Olsson-Strömberg U; Själander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S; Bykov VJN; Ali D; Andrén O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: HAEMATOLOGICA. 2012;97(9):1380-1388

A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies.

Grønbæk K; Müller-Tidow C; Perini G; Lehmann S; Bach Treppendahl M; Mills K; Plass C; Schlegelberger B; European Genomics and Epigenomics Study on MDS and
Article: BLOOD. 2011;118(20):5573-5582

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.

Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzén S; Nahi H; Uggla B; Tidefelt U; Höglund M; Paul C; Ekwall K; Döhner K; Lehmann S
Article: CANCER. 2011;117(18):4238-4246

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.

Juliusson G; Karlsson K; Lazarevic VL; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M; Swedish Acute Leukemia Registry Group, the Swedish
Article: LEUKEMIA. 2011;25(7):1128-1134

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;86(3):206-215

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.

Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
Article: LEUKEMIA. 2010;24(5):932-941

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.

Deneberg S; Grövdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Döhner K; Paul C; Ekström TJ; Hellström-Lindberg E; Lehmann S
Article: CANCER LETTERS. 2009;282(1):116-123

Selenite is a potent cytotoxic agent for human primary AML cells.

Olm E; Jönsson-Videsäter K; Ribera-Cortada I; Fernandes AP; Eriksson LC; Lehmann S; Rundlöf A-K; Paul C; Björnstedt M
Article: HAEMATOLOGICA. 2009;94(9):1301-1306

Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells.

Akagi T; Shih L-Y; Ogawa S; Gerss J; Moore SR; Schreck R; Kawamata N; Liang D-C; Sanada M; Nannya Y; Deneberg S; Zachariadis V; Nordgren A; Song JH; Dugas M; Lehmann S; Koeffler HP
Article: BLOOD. 2009;113(18):4179-4187

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Juliusson G; Antunovic P; Derolf A; Lehmann S; Möllgård L; Stockelberg D; Tidefelt U; Wahlin A; Höglund M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62(3):439-448

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: CANCER. 2008;112(6):1296-1305

Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia.

Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
Article: LEUKEMIA & LYMPHOMA. 2008;49(3):508-516

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
Article: THERAPEUTIC DRUG MONITORING. 2007;29(5):626-631

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.

Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Article: LEUKEMIA. 2007;21(9):1931-1936

Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.

Lehmann S; O'Kelly J; Raynaud S; Funk SE; Sage EH; Koeffler HP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.

Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Article: NATURE MEDICINE. 2005;11(6):630-637

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.

Castor A; Nilsson L; Astrand-Grundström I; Buitenhuis M; Ramirez C; Anderson K; Strömbeck B; Garwicz S; Békássy AN; Schmiegelow K; Lausen B; Hokland P; Lehmann S; Juliusson G; Johansson B; Jacobsen SEW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Article: BIOCHEMICAL PHARMACOLOGY. 2002;63(10):1875-1884

Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.

Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Article: LEUKEMIA & LYMPHOMA. 2002;43(4):851-858

The expression of cellular retinoid binding proteins in non-APL leukemic cells and its association with retinoid sensitivity.

Lehmann S; Paul C; Törmä H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(6):357-364

Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.

Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;26(2):187-192

Cardiac systolic function before and after hematopoietic stem cell transplantation.

Lehmann S; Isberg B; Ljungman P; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):993-996

N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation.

Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
Article: LEUKEMIA RESEARCH. 2000;24(1):19-25

Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML.

Lehmann S; Bengtzen S; Broberg U; Paul C
Show more

All other publications

Letter: BLOOD ADVANCES. 2021;5(3):787-790

Impact of treatment delay in acute myeloid leukemia revisited.

Juliusson G; Hagberg O; Lazarevic VL; Lehmann S; Höglund M
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):e13-e16

Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.

Österroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Möllgård L; Derolf ÅR; Uggla B; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(1):187-191

Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.

Derolf Å; Juliusson G; Benson L; Fløisand Y; Lazarevic V; Antunovic P; Möllgård L; Lehmann S; Uggla B; Wahlin A; Höglund M; Deneberg S
Editorial comment: HAEMATOLOGICA. 2020;105(2):249-251

Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people.

Juliusson G; Höglund M; Lehmann S
Letter: BLOOD. 2019;134(18):1558-1561

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Juliusson G; Hagberg O; Lazarevic VL; Ölander E; Antunovic P; Cammenga J; Wennström L; Möllgård L; Brune M; Jädersten M; Deneberg S; Lehmann S; Derolf ÅR; Höglund M
Letter: LEUKEMIA. 2017;31(6):1457-1459

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.

Lehmann S; Deneberg S; Antunovic P; Rangert-Derolf Å; Garelius H; Lazarevic V; Myhr-Eriksson K; Möllgård L; Uggla B; Wahlin A; Wennström L; Höglund M; Juliusson G
Letter: LEUKEMIA. 2017;31(3):728-731

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.

Juliusson G; Abrahamsson J; Lazarevic V; Antunovic P; Derolf Å; Garelius H; Lehmann S; Myhr-Eriksson K; Möllgård L; Uggla B; Wahlin A; Wennström L; Höglund M; Swedish AML Group and the Swedish Childhood Leukem
Letter: BLOOD CANCER JOURNAL. 2016;6(7):e447

An open-label phase I dose-finding study of APR-246 in hematological malignancies.

Deneberg S; Cherif H; Lazarevic V; Andersson P-O; von Euler M; Juliusson G; Lehmann S
Letter: HAEMATOLOGICA. 2015;100(6):e223-e225

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellström-Lindberg E
Review: ALLERGY. 2008;63(7):842-853

Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper.

Bousquet J; Fokkens W; Burney P; Durham SR; Bachert C; Akdis CA; Canonica GW; Dahlen S-E; Zuberbier T; Bieber T; Bonini S; Bousquet PJ; Brozek JL; Cardell L-O; Crameri R; Custovic A; Demoly P; van Wijk RG; Gjomarkaj M; Holland C; Howarth P; Humbert M; Johnston SL; Kauffmann F; Kowalski ML; Lambrecht B; Lehmann S; Leynaert B; Lodrup-Carlsen K; Mullol J; Niggemann B; Nizankowska-Mogilnicka E; Papadopoulos N; Passalacqua G; Schünemann HJ; Simon H-U; Todo-Bom A; Toskala E; Valenta R; Wickman M; Zock JP
Meeting abstract: BLOOD. 2007;110(11):161B

Factors affecting long-term survival in non-transplanted acute myeloid leukemia patients

Lof AH; Lehmann S
Meeting abstract: BLOOD. 2007;110(11):133B

Expression of p14ARF in de novo AML with normal karyotype.: Implication on drug resistance and survival

Paul EO; Deneberg S; Lehmann S; Bengtzen S; Nahi H
Meeting abstract: BLOOD. 2004;104(11):501A

Effects of the FLT3 inhibitor PKC 412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

Möllgård L; Bengtzen S; Fioretos T; Andersson A; Paul C; Lehmann S
Corrigendum: BIOCHEMICAL PHARMACOLOGY. 2002;64(1):159

Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase (vol 63, pg 1875, 2002)

Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Published paper: CLINICAL CANCER RESEARCH. 2001;7(2):367-373

Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells.

Lehmann S; Paul C; Törmä H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2000;108(1):198-199

The retinoic acid syndrome in non-M3 acute myeloid leukaemia: a case report.

Lehmann S; Paul C
Review: LAKARTIDNINGEN. 1999;96(50):5626-5628

[Arsenic efficient in acute promyelocytic leukemia].

Lehmann S; Paul C

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska Institutet, 2010
Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2002
University Medical Degree, Karolinska Institutet, 1992

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI